First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
Neurosci Bull. 2024 Mar;40(3):383-400. doi: 10.1007/s12264-023-01110-0. Epub 2023 Sep 16.
Neurological manifestations of coronavirus disease 2019 (COVID-19) are less noticeable than the respiratory symptoms, but they may be associated with disability and mortality in COVID-19. Even though Omicron caused less severe disease than Delta, the incidence of neurological manifestations is similar. More than 30% of patients experienced "brain fog", delirium, stroke, and cognitive impairment, and over half of these patients presented abnormal neuroimaging outcomes. In this review, we summarize current advances in the clinical findings of neurological manifestations in COVID-19 patients and compare them with those in patients with influenza infection. We also illustrate the structure and cellular invasion mechanisms of SARS-CoV-2 and describe the pathway for central SARS-CoV-2 invasion. In addition, we discuss direct damage and other pathological conditions caused by SARS-CoV-2, such as an aberrant interferon response, cytokine storm, lymphopenia, and hypercoagulation, to provide treatment ideas. This review may offer new insights into preventing or treating brain damage in COVID-19.
新型冠状病毒病 2019(COVID-19)的神经系统表现不如呼吸道症状明显,但可能与 COVID-19 的残疾和死亡率有关。尽管奥密克戎引起的疾病比德尔塔病毒轻,但神经系统表现的发生率相似。超过 30%的患者出现“脑雾”、意识混乱、中风和认知障碍,超过一半的患者出现异常神经影像学结果。在这篇综述中,我们总结了 COVID-19 患者神经系统表现的临床发现的最新进展,并将其与流感感染患者的进行了比较。我们还说明了 SARS-CoV-2 的结构和细胞入侵机制,并描述了中枢神经系统 SARS-CoV-2 入侵的途径。此外,我们讨论了由 SARS-CoV-2 引起的直接损伤和其他病理情况,如异常干扰素反应、细胞因子风暴、淋巴细胞减少和高凝状态,以提供治疗思路。这篇综述可能为预防或治疗 COVID-19 中的脑损伤提供新的思路。